CIPLA (CIPLA) News
Follow CIPLA (CIPLA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Linux Laboratories raises $70 mn led by ChrysCapital and Tata Capital
Mumbai, Sept. 30 -- Linux Laboratories Pvt. Ltd, one of India's fastest-growing domestic formulations companies, raised $70 million from ChrysCapital and Tata Capital Healthcare Fund III, the company said in a statement
NEWS | Sep 30, 2026, 03:36 AM UTC
L
India plans central licensing for all sterile drug products
India plans to bring all sterile drug products under a central licensing system, tightening oversight of injectables and other sterile medicines. The plan follows about 240 injection samples found not to be of standard q
REGULATION | Sep 10, 2026, 04:38 PM UTC
L
Morgan Stanley keeps Underweight on Cipla; target ₹1,218
Cipla shares traded lower on Sept. 4 after Morgan Stanley retained an Underweight rating and set a target price of ₹1,218, the second-lowest among analysts covering the stock.
EQUITY | Sep 04, 2026, 08:07 AM UTC
L
Cipla shares slip as Keytruda biosimilar pact with Qilu weighs
Cipla shares traded marginally lower on Friday amid a strong broader market after its partnership with China’s Qilu Pharmaceutical for a Keytruda biosimilar. The new deal is expected to bolster Cipla’s oncology and speci
GEOPOLITICS | Sep 04, 2026, 05:46 AM UTC
L
Top stocks to watch today: Reason why these shares are in focus for Friday's trading session | Full list
New Delhi, Sept. 3 -- Indian stock market investors are likely to track several companies on Friday, 4 September, following key business developments, order wins, fundraising plans, and investment announcements made afte
EQUITY | Sep 04, 2026, 04:36 AM UTC
L
Top stocks to watch tomorrow, Sept 4 and reasons why they are in focus for Friday's trading session
New Delhi, Sept. 3 -- Indian stock market investors are likely to track several companies on Friday, 4 September, following key business developments, order wins, fundraising plans, and investment announcements made afte
EQUITY | Sep 03, 2026, 09:03 PM UTC
M
Cipla partners with Qilu Pharmaceutical to license, supply biosimilar Keytruda
Cipla says it has partnered with Qilu Pharmaceutical for licensing and supply of a biosimilar to Keytruda for use in the US.
EQUITY | Sep 03, 2026, 05:29 PM UTC
M
Cipla subsidiary Invagen signs partnership with Qilu on biosimilar licensing
Invagen Pharmaceuticals, a wholly owned subsidiary of Cipla, announced a strategic partnership with Qilu for the licensing and supply of a biosimilar to Keytruda (pembrolizumab) in the US.
EQUITY | Sep 03, 2026, 04:47 PM UTC
M
Cipla partners with Qilu to license Keytruda biosimilar for U.S.
India’s Cipla said its U.S. unit entered an exclusive partnership with China’s Qilu Pharmaceutical to license a biosimilar version of Merck’s Keytruda for the U.S. market.
GEOPOLITICS | Sep 03, 2026, 03:23 PM UTC
L
Cipla signs exclusive US partnership with Qilu for Keytruda biosimilar
Cipla Ltd says it has entered an exclusive partnership with Qilu covering a Keytruda biosimilar in the US.
EQUITY | Sep 03, 2026, 02:42 PM UTC
M
India Centre plans biologics vs synthetics distinction in drug rules
India’s Centre plans changes to the Drugs Rules, 1945 to require pharmaceutical companies to clearly distinguish biologics from synthetic drugs when seeking licences and on packaging, per two government officials.
EQUITY | Sep 02, 2026, 04:08 AM UTC
L
Sun Pharma and Cipla seen as having more upside
Systematix analyst Vishal Manchanda said Sun Pharmaceutical Industries and Cipla offer relatively better upside among large-cap pharma stocks. He added that increasing licensing deals with Chinese drugmakers could help l
EQUITY | Sep 01, 2026, 10:47 AM UTC
L
Cipla shares rise on cancer drug licensing deal with Sino Biopharma arm
Cipla shares gained after it inked a cancer treatment drug licensing deal with Sino Biopharma’s arm.
EQUITY | Sep 01, 2026, 03:57 AM UTC
L
Bombay HC pulls up Maharashtra FDA over enforcement actions: What businesses need to know
Bombay HC pulls up Maharashtra FDA over enforcement actions: What businesses need to know
REGULATION | Aug 30, 2026, 04:21 PM UTC
L
US FDA flags Cipla New York facility inspection with VAI
US FDA classifies Cipla subsidiary’s New York facility inspection as “Voluntary Action Indicated.”
REGULATION | Aug 29, 2026, 10:07 AM UTC